Spero Therapeutics (SPRO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SPRO Stock Forecast

Spero Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

SPRO Analyst Ratings

Buy

According to 3 Wall Street analysts, Spero Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SPRO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Nov 18, 2024	Cowen & Co.	Buy	Hold	Downgrade
Oct 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 06, 2024	Cowen & Co.		Buy	Upgrade
Sep 22, 2022	Evercore ISI		Outperform	Upgrade

Spero Therapeutics's last stock rating was published by H.C. Wainwright on Dec 02, 2024. The company gave SPRO a "Buy" rating, the same as its previous rate.

Spero Therapeutics Financial Forecast

Spero Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
Revenue	-	-	-	-	-	-	-	-	$71.83M	$25.47M	$2.72M	$740.00K	$46.30M	$1.08M	$896.00K	$247.00K	$2.74M	$3.06M	$5.15M	$7.30M	$1.91M	$4.00M	$1.73M	$1.70M	$3.63M	$4.64M	$2.16M	$7.72M	$1.15M
Avg Forecast	$26.00M	$12.00M	$11.00M	$11.00M	$6.20M	$23.00M	$4.90M	$21.53M	$18.63M	$14.97M	$1.08M	$1.27M	$866.67K	$5.42M	$1.43M	$1.93M	$4.95M	$4.47M	$4.53M	$3.75M	$3.67M	$3.01M	$3.31M	$3.44M	$3.91M	$2.45M	$6.31M	$2.83M	$1.87M
High Forecast	$26.00M	$12.00M	$11.00M	$11.00M	$6.20M	$23.00M	$4.90M	$21.53M	$18.63M	$14.97M	$1.08M	$1.27M	$866.67K	$5.42M	$1.43M	$1.93M	$4.95M	$4.47M	$4.53M	$3.75M	$3.67M	$3.01M	$3.31M	$3.44M	$3.91M	$2.45M	$6.31M	$2.83M	$2.24M
Low Forecast	$26.00M	$12.00M	$11.00M	$11.00M	$6.20M	$23.00M	$4.90M	$21.53M	$18.63M	$14.97M	$1.08M	$1.27M	$866.67K	$5.42M	$1.43M	$1.93M	$4.95M	$4.47M	$4.53M	$3.75M	$3.67M	$3.01M	$3.31M	$3.44M	$3.91M	$2.45M	$6.31M	$2.83M	$1.50M
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9
Surprise %	-	-	-	-	-	-	-	-	3.85%	1.70%	2.51%	0.58%	53.42%	0.20%	0.63%	0.13%	0.55%	0.69%	1.14%	1.95%	0.52%	1.33%	0.52%	0.49%	0.93%	1.89%	0.34%	2.73%	0.62%

Spero Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $21.53M, with a low forecast of $21.53M, and a high forecast of $21.53M. SPRO's average Quarter revenue forecast represents a -70.02% decrease compared to the company's last Quarter revenue of $71.83M (Dec 23).

Spero Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9
EBITDA	-	-	-	-	-	-	-	-	$48.87M	$-1.93M	$-12.89M	$-13.15M	$25.79M	$-11.54M	$-13.84M	$-29.96M	$-27.11M	$-22.37M	$-18.42M	$-19.26M	$-18.39M	$-18.75M	$-17.31M	$-23.07M	$-25.10M	$-17.23M	$-12.96M	$-4.89M	$-10.55M
Avg Forecast	$-18.74M	$-8.65M	$-7.93M	$-7.93M	$-4.47M	$-16.58M	$-3.53M	$-15.52M	$-13.43M	$-10.79M	$-780.77K	$-912.91K	$-624.62K	$-3.45M	$-912.16K	$-1.23M	$-3.15M	$-2.84M	$-2.88M	$-18.66M	$-2.34M	$-1.91M	$-2.11M	$-23.62M	$-2.49M	$-1.56M	$-4.02M	$-7.16M	$-14.59M
High Forecast	$-18.74M	$-8.65M	$-7.93M	$-7.93M	$-4.47M	$-16.58M	$-3.53M	$-15.52M	$-13.43M	$-10.79M	$-780.77K	$-912.91K	$-624.62K	$-3.45M	$-912.16K	$-1.23M	$-3.15M	$-2.84M	$-2.88M	$-14.93M	$-2.34M	$-1.91M	$-2.11M	$-18.90M	$-2.49M	$-1.56M	$-4.02M	$-5.73M	$-11.67M
Low Forecast	$-18.74M	$-8.65M	$-7.93M	$-7.93M	$-4.47M	$-16.58M	$-3.53M	$-15.52M	$-13.43M	$-10.79M	$-780.77K	$-912.91K	$-624.62K	$-3.45M	$-912.16K	$-1.23M	$-3.15M	$-2.84M	$-2.88M	$-22.39M	$-2.34M	$-1.91M	$-2.11M	$-28.35M	$-2.49M	$-1.56M	$-4.02M	$-8.60M	$-17.51M
Surprise %	-	-	-	-	-	-	-	-	-3.64%	0.18%	16.51%	14.41%	-41.29%	3.35%	15.17%	24.46%	8.61%	7.87%	6.40%	1.03%	7.87%	9.80%	8.21%	0.98%	10.08%	11.04%	3.23%	0.68%	0.72%

1 analysts predict SPRO's average Quarter EBITDA for Mar 24 to be $-15.52M, with a high of $-15.52M and a low of $-15.52M. This is -131.75% lower than Spero Therapeutics's previous annual EBITDA (Dec 23) of $48.87M.

Spero Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9
Net Income	-	-	-	-	-	-	-	-	$51.19M	$-3.21M	$-11.91M	$-12.30M	$26.77M	$-11.52M	$-31.28M	$-35.45M	$-31.18M	$-22.52M	$-18.57M	$-19.42M	$-18.59M	$-18.94M	$-17.50M	$-23.26M	$-24.99M	$-17.72M	$-13.15M	$-5.07M	$-10.64M
Avg Forecast	$-5.14M	$-11.64M	$-13.53M	$-14.34M	$-22.01M	$-14.34M	$-20.57M	$-2.35M	$-5.41M	$-1.62M	$-18.58M	$-18.04M	$-19.12M	$-16.37M	$-50.00M	$-50.18M	$-40.33M	$-35.79M	$-40.47M	$-18.82M	$-39.50M	$-47.16M	$-60.43M	$-23.82M	$-57.91M	$-45.32M	$-34.53M	$-7.43M	$-14.72M
High Forecast	$-5.14M	$-11.64M	$-13.53M	$-14.34M	$-19.17M	$-14.34M	$-20.57M	$-2.35M	$-1.80M	$-1.62M	$-18.58M	$-18.04M	$-19.12M	$-16.37M	$-50.00M	$-50.18M	$-40.33M	$-35.79M	$-40.47M	$-15.05M	$-39.50M	$-47.16M	$-60.43M	$-19.05M	$-57.91M	$-45.32M	$-34.53M	$-5.95M	$-11.78M
Low Forecast	$-5.14M	$-11.64M	$-13.53M	$-14.34M	$-24.85M	$-14.34M	$-20.57M	$-2.35M	$-8.72M	$-1.62M	$-18.58M	$-18.04M	$-19.12M	$-16.37M	$-50.00M	$-50.18M	$-40.33M	$-35.79M	$-40.47M	$-22.58M	$-39.50M	$-47.16M	$-60.43M	$-28.58M	$-57.91M	$-45.32M	$-34.53M	$-8.92M	$-17.67M
Surprise %	-	-	-	-	-	-	-	-	-9.46%	1.97%	0.64%	0.68%	-1.40%	0.70%	0.63%	0.71%	0.77%	0.63%	0.46%	1.03%	0.47%	0.40%	0.29%	0.98%	0.43%	0.39%	0.38%	0.68%	0.72%

Spero Therapeutics's average Quarter net income forecast for Mar 24 is $-2.35M, with a range of $-2.35M to $-2.35M. SPRO's average Quarter net income forecast represents a -104.58% decrease compared to the company's last Quarter net income of $51.19M (Dec 23).

Spero Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9
SG&A	-	-	-	-	-	-	-	-	$6.43M	$5.71M	$6.10M	$7.32M	$6.50M	$6.63M	$8.05M	$15.30M	$13.02M	$11.15M	$9.23M	$8.30M	$7.50M	$5.31M	$4.55M	$4.09M	$3.79M	$4.13M	$3.78M	$3.89M	$3.04M
Avg Forecast	$46.20M	$21.32M	$19.55M	$19.55M	$11.02M	$40.87M	$8.71M	$38.26M	$33.11M	$26.59M	$1.92M	$2.25M	$1.54M	$9.62M	$2.55M	$3.42M	$8.80M	$7.94M	$8.04M	$6.66M	$6.52M	$5.34M	$5.89M	$6.12M	$6.95M	$4.36M	$11.22M	$5.02M	$3.32M
High Forecast	$46.20M	$21.32M	$19.55M	$19.55M	$11.02M	$40.87M	$8.71M	$38.26M	$33.11M	$26.59M	$1.92M	$2.25M	$1.54M	$9.62M	$2.55M	$3.42M	$8.80M	$7.94M	$8.04M	$6.66M	$6.52M	$5.34M	$5.89M	$6.12M	$6.95M	$4.36M	$11.22M	$5.02M	$3.99M
Low Forecast	$46.20M	$21.32M	$19.55M	$19.55M	$11.02M	$40.87M	$8.71M	$38.26M	$33.11M	$26.59M	$1.92M	$2.25M	$1.54M	$9.62M	$2.55M	$3.42M	$8.80M	$7.94M	$8.04M	$6.66M	$6.52M	$5.34M	$5.89M	$6.12M	$6.95M	$4.36M	$11.22M	$5.02M	$2.66M
Surprise %	-	-	-	-	-	-	-	-	0.19%	0.21%	3.17%	3.25%	4.22%	0.69%	3.16%	4.47%	1.48%	1.41%	1.15%	1.25%	1.15%	0.99%	0.77%	0.67%	0.54%	0.95%	0.34%	0.77%	0.92%

Spero Therapeutics's average Quarter SG&A projection for Mar 24 is $38.26M, based on 1 Wall Street analysts, with a range of $38.26M to $38.26M. The forecast indicates a 494.79% rise compared to SPRO last annual SG&A of $6.43M (Dec 23).

Spero Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9
EPS	-	-	-	-	-	-	-	-	$0.96	$-0.06	$-0.00	$-0.23	$-0.98	$-0.32	$-0.95	$-1.09	$-0.97	$-0.70	$-0.63	$-0.66	$-0.68	$-0.86	$-0.85	$-1.22	$-1.32	$-0.95	$-0.74	$-0.29	$-0.74
Avg Forecast	$-0.10	$-0.21	$-0.25	$-0.27	$-0.41	$-0.27	$-0.38	$-0.04	$-0.10	$-0.03	$-0.34	$-0.33	$-0.35	$-0.30	$-0.93	$-0.93	$-0.75	$-0.66	$-0.75	$-0.63	$-0.73	$-0.87	$-1.12	$-1.24	$-1.07	$-0.84	$-0.64	$-0.77	$-1.66
High Forecast	$-0.10	$-0.21	$-0.25	$-0.27	$-0.35	$-0.27	$-0.38	$-0.04	$-0.03	$-0.03	$-0.34	$-0.33	$-0.35	$-0.30	$-0.93	$-0.93	$-0.75	$-0.66	$-0.75	$-0.63	$-0.73	$-0.87	$-1.12	$-1.24	$-1.07	$-0.84	$-0.64	$-0.77	$-1.33
Low Forecast	$-0.10	$-0.21	$-0.25	$-0.27	$-0.46	$-0.27	$-0.38	$-0.04	$-0.16	$-0.03	$-0.34	$-0.33	$-0.35	$-0.30	$-0.93	$-0.93	$-0.75	$-0.66	$-0.75	$-0.63	$-0.73	$-0.87	$-1.12	$-1.24	$-1.07	$-0.84	$-0.64	$-0.77	$-1.99
Surprise %	-	-	-	-	-	-	-	-	-9.60%	2.03%	0.00%	0.69%	2.77%	1.05%	1.03%	1.17%	1.30%	1.06%	0.84%	1.05%	0.93%	0.98%	0.76%	0.98%	1.23%	1.13%	1.16%	0.38%	0.45%

According to 1 Wall Street analysts, Spero Therapeutics's projected average Quarter EPS for Mar 24 is $-0.04, with a low estimate of $-0.04 and a high estimate of $-0.04. This represents a -104.51% decrease compared to SPRO previous annual EPS of $0.96 (Dec 23).

Spero Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
TIL	Instil Bio	$21.69	$150.00	591.56%	Hold
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
NUVB	Nuvation Bio	$2.81	$7.00	149.11%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
ACHL	Achilles Therapeutics	$0.97	$2.00	106.19%	Buy

SPRO Forecast FAQ

Is Spero Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Spero Therapeutics (SPRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of SPRO's total ratings.

What are Spero Therapeutics's analysts' financial forecasts?

Spero Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $55.63M (high $55.63M, low $55.63M), average EBITDA is $-40.096M (high $-40.096M, low $-40.096M), average net income is $-59.267M (high $-56.427M, low $-62.107M), average SG&A $98.86M (high $98.86M, low $98.86M), and average EPS is $-1.095 (high $-1.043, low $-1.147). SPRO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $60M (high $60M, low $60M), average EBITDA is $-43.243M (high $-43.243M, low $-43.243M), average net income is $-44.653M (high $-44.653M, low $-44.653M), average SG&A $106.62M (high $106.62M, low $106.62M), and average EPS is $-0.825 (high $-0.825, low $-0.825).

Did the SPRO's actual financial results beat the analysts' financial forecasts?

Based on Spero Therapeutics's last annual report (Dec 2023), the company's revenue was $96.74M, beating the average analysts forecast of $35.95M by 169.08%. Apple's EBITDA was $20.11M, missing the average prediction of $-25.91M by -177.61%. The company's net income was $22.81M, missing the average estimation of $-43.66M by -152.24%. Apple's SG&A was $25.55M, missing the average forecast of $63.88M by -60.00%. Lastly, the company's EPS was $0.43, missing the average prediction of $-0.807 by -153.31%. In terms of the last quarterly report (Dec 2023), Spero Therapeutics's revenue was $71.83M, beating the average analysts' forecast of $18.63M by 285.48%. The company's EBITDA was $48.87M, missing the average prediction of $-13.429M by -463.93%. Spero Therapeutics's net income was $51.19M, missing the average estimation of $-5.412M by -1045.81%. The company's SG&A was $6.43M, missing the average forecast of $33.11M by -80.57%. Lastly, the company's EPS was $0.96, missing the average prediction of $-0.1 by -1060.00%